BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33948563)

  • 1. Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults.
    Ji J; Kaneva K; Hiemenz MC; Dhall G; Davidson TB; Erdreich-Epstein A; Hawes D; Hurth K; Margol AS; Mathew AJ; Robison NJ; Schmidt RJ; Tran HN; Judkins AR; Cotter JA; Biegel JA
    Neurooncol Adv; 2021; 3(1):vdab037. PubMed ID: 33948563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors.
    Mukherjee S; Ma Z; Wheeler S; Sathanoori M; Coldren C; Prescott JL; Kozyr N; Bouzyk M; Correll M; Ho H; Chandra PK; Lennon PA
    Cancer Genet; 2016 Apr; 209(4):119-29. PubMed ID: 26880400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
    Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
    Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
    Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
    Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors.
    Rajappa P; Eng KW; Bareja R; Bander ED; Yuan M; Dua A; Bhanu Maachani U; Snuderl M; Pan H; Zhang T; Tosi U; Ivasyk I; Souweidane MM; Elemento O; Sboner A; Greenfield JP; Pisapia DJ
    Neurooncol Adv; 2022; 4(1):vdac031. PubMed ID: 35475276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Variants in Cancer Predisposition Genes in Pediatric Patients with Central Nervous System Tumors.
    Jovanović A; Tošić N; Marjanović I; Komazec J; Zukić B; Nikitović M; Ilić R; Grujičić D; Janić D; Pavlović S
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of custom-designed NGS panel testing in pediatric tumors.
    Surrey LF; MacFarland SP; Chang F; Cao K; Rathi KS; Akgumus GT; Gallo D; Lin F; Gleason A; Raman P; Aplenc R; Bagatell R; Minturn J; Mosse Y; Santi M; Tasian SK; Waanders AJ; Sarmady M; Maris JM; Hunger SP; Li MM
    Genome Med; 2019 May; 11(1):32. PubMed ID: 31133068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
    Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
    Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies.
    Hiemenz MC; Oberley MJ; Doan A; Aye L; Ji J; Schmidt RJ; Biegel JA; Bhojwani D; Raca G
    Cancer Genet; 2021 Jun; 254-255():25-33. PubMed ID: 33571894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of copy number variant detection from panel-based next-generation sequencing data.
    Yao R; Yu T; Qing Y; Wang J; Shen Y
    Mol Genet Genomic Med; 2019 Jan; 7(1):e00513. PubMed ID: 30565893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous Detection of
    Bianchessi D; Ibba MC; Saletti V; Blasa S; Langella T; Paterra R; Cagnoli GA; Melloni G; Scuvera G; Natacci F; Cesaretti C; Finocchiaro G; Eoli M
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32575496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.
    Fukuhara S; Oshikawa-Kumade Y; Kogure Y; Shingaki S; Kariyazono H; Kikukawa Y; Koya J; Saito Y; Tabata M; Yoshifuji K; Mizuno K; Miyagi-Maeshima A; Matsushita H; Sugiyama M; Ogawa C; Inamoto Y; Fukuda T; Sugano M; Yamauchi N; Minami Y; Hirata M; Yoshida T; Kohno T; Kohsaka S; Mano H; Shiraishi Y; Ogawa S; Izutsu K; Kataoka K
    Cancer Sci; 2022 Aug; 113(8):2763-2777. PubMed ID: 35579198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
    Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
    Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive Diagnostic Yield of Homozygosity Regions Identified During Chromosomal microarray Testing in Children with Developmental Delay, Dysmorphic Features or Congenital Anomalies.
    Ali MAM; Hassan AM; Saafan MA; Abdelmagid AA
    Biochem Genet; 2020 Feb; 58(1):74-101. PubMed ID: 31273557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
    Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
    Beg S; Bareja R; Ohara K; Eng KW; Wilkes DC; Pisapia DJ; Zoughbi WA; Kudman S; Zhang W; Rao R; Manohar J; Kane T; Sigouros M; Xiang JZ; Khani F; Robinson BD; Faltas BM; Sternberg CN; Sboner A; Beltran H; Elemento O; Mosquera JM
    Transl Oncol; 2021 Jan; 14(1):100944. PubMed ID: 33190043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
    Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
    BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience.
    Marks LJ; Oberg JA; Pendrick D; Sireci AN; Glasser C; Coval C; Zylber RJ; Chung WK; Pang J; Turk AT; Hsiao SJ; Mansukhani MM; Glade Bender JL; Kung AL; Sulis ML
    Front Pediatr; 2017; 5():265. PubMed ID: 29312904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.